Rehaler has been tested in a randomized, controlled, double-blind clinical trial on migraine with aura, which showed significantly higher user satisfaction and pain relief compared to placebo. 78% of attacks had pain relief already at the second treatment. Large follow-up studies are now in preparation, focusing on several different types of migraine.
The clinical trial of Rehaler was conducted by the Headache Clinic at Aarhus University Hospital in Denmark. The results of the study were in August 2018 published in Cephalalgia which is the highest-ranked scientific headache journal in the world. The article can be accessed for free here.
Rehaler received CE approval and entered the European market in 2018.
Please note: Any recommendation given on this website cannot replace a healthcare professional’s direction or diagnosis. If you are unsure, please consult with your healthcare practitioner.
Rehaler – © 2021 / CVR: 41553456
Rehaler ApS, Absalongade 26, 8000 Aarhus C , Denmark
We use cookies to deliver content, for statistics and to improve your experience on the site. By using rehaler.com you accept the terms for the use of cookies.